Primary hyperparathyroidism and vitamin D deficiency

Area of Science:

• Endocrinology
• Metabolic Diseases
• Nutritional Science

Background:

• Primary hyperparathyroidism (PHPT) and vitamin D (VD) deficiency are common, often co-occurring endocrine and metabolic conditions.
• PHPT presents with diverse symptoms, increasingly in asymptomatic forms, impacting calcium and phosphate homeostasis.
• Vitamin D deficiency exacerbates bone and cardiometabolic complications in PHPT, with prevalence influenced by various factors.

Purpose of the Study:

• To assess the impact and safety of vitamin D supplementation in patients with primary hyperparathyroidism and vitamin D deficiency.
• To evaluate the effect of vitamin D replacement on hyperparathyroidism, bone health, and cardiometabolic parameters.

Main Methods:

• Systematic assay of vitamin D levels in patients with PHPT was validated.
• Epidemiological studies confirmed the safety and tolerability of natural vitamin D replacement.
• Clinical outcomes including bone condition, functional status, and calciuria were monitored.

Main Results:

• Vitamin D replacement in PHPT patients with deficiency is well-tolerated and safe.
• Supplementation effectively reduces hyperparathyroidism levels (hyperparathormonemia).
• Significant improvements were observed in bone health and the functional status of patients.

Conclusions:

• Systematic screening and replacement of vitamin D deficiency in PHPT patients is recommended.
• Vitamin D supplementation offers a safe and effective strategy to manage complications associated with PHPT and VD deficiency.
• This approach improves patient outcomes, particularly bone and functional health.